



شماره پذیرش:

مراجعه: آقا

سن: ۶۸ سال

اشتراک:

پزشک معالج:

تاریخ پذیرش:

صفحه: ۱ از ۲ سابقه: ۹

## Hematology

	<u>Result</u>		<u>Unit</u>	<u>Method</u>	<u>Reference Interval</u>
<b>C.B.C</b>					
<b>Cell Count</b>					
WBC	<b>18.99</b>	<b>H</b>	1000/ $\mu$ L		4-11
RBC	<b>6.11</b>	<b>H</b>	Mil/ $\mu$ L		4.7-6.1
Hemoglobin	<b>15.8</b>		g/dL		14-18
Hematocrit	<b>49.4</b>		%		42-52
MCV	<b>80.9</b>		fl		80-96
MCH	<b>25.9</b>	<b>L</b>	pg		27-32
MCHC	<b>32</b>	<b>L</b>	g/dL		33-36
RDW	<b>15.8</b>	<b>H</b>	%		11.5-14.5
Platelet	<b>827</b>	<b>H</b>	1000/ $\mu$ L		145-449

### Platelets Morphology

Large & Giant Platelets **Seen**

### RBC Morphology

Anisocytosis **1+**

Hypochromia **1+**

Microcytosis **1+**

Ovalocytosis **1+**

### Leukocyte Differential

#### Count

Neutrophil#	<b>16.63</b>	<b>H</b>	$\times$ 1000/ $\mu$ L		1.8-7
Lymphocyte#	<b>1.12</b>	<b>L</b>	$\times$ 1000/ $\mu$ L		1.5-4
Monocyte#	<b>0.46</b>		$\times$ 1000/ $\mu$ L		0.12-0.8
Eosinophil#	<b>0.63</b>	<b>H</b>	$\times$ 1000/ $\mu$ L		0.02-0.35
Basophil#	<b>0.15</b>		$\times$ 1000/ $\mu$ L		0.0-0.2
Neutrophil%	<b>76</b>	<b>H</b>	%		50-70
Lymphocyte%	<b>7</b>	<b>L</b>	%		20-40
Monocyte%	<b>3</b>		%		3-12
Band Cell%	<b>9</b>	<b>H</b>	%		0-6%
Eosinophil%	<b>3</b>		%		0.5-5
Basophil%	<b>2</b>	<b>H</b>	%		0-1

### WBC Morphology

Toxic granulation **1+**

نمونه ۹۹۲۲۲۰

## Myeloproliferative Neoplasms Panel

**Patient:**  
**Age:** 68 Y/O  
**Melli code:**  
**Phone:**  
**Specimen ID:**  
**Specimen Type:** EDTA Anticoagulated Peripheral Blood

**Physician:** Dr.  
**Specialty:** Hematologist & Oncologist  
**Received:**  
**Reported:**

### Test Result:

<b>JAK2-V617F Mutation</b>	<b>Detected</b>
<b>MPL W515 K Mutation</b>	Not Requested
<b>MPL W515 L Mutation</b>	Not Requested
<b>Calreticulin exon9 Mutation</b>	Not Requested
<b>*MPL S505N Mutation</b>	Not Requested

**Application:** JAK2 pV617F (c. 1849G>T) mutation determined as an acquired mutation in most patients with Polycythaemia Vera, but only in half those with **Essential Thrombocythaemia** and **Idiopathic Myelofibrosis**.

MPL W515 L/K and MPL S505N mutations are investigated as acquired mutations occurring in JAK2-V617F mutation negative MPDs, primary Myelofibrosis & Essential Thrombocythaemia. MPL S505N mutation analysis can also be ordered in suspected patients for hereditary thrombocythemia.

Identification of CALR (Calreticulin) exon9 mutation for diagnosis and sub classification of Myeloproliferative Neoplasm in JAK2 and MPL negative patients.

**Method:** Genomic DNA was extracted and allele specific PCR was done in duplicate for each sample.

\* MPL S505N is detected by PCR - RFLP method.

# نمونه ۹۹۲۲۲۱

شماره پذیرش		سن ۸۴ سال		شماره برگ		تاریخ پذیرش	
سراجعه خانم						شماره ۶	
<b>hematology</b>							
<b>C.B.C</b>							
<b>Cell Count</b>							
WBC	8.88			1000/ $\mu$ L			4-11
RBC	4.07	L		Mil/ $\mu$ L			4.2-5.4
Hemoglobin	8.4	L		g/dL			12-16
Hematocrit	27.6	L		%			37-47
MCV	67.8	L		fL			80-96
MCH	20.6	L		pg			27-32
MCHC	30.4	L		g/dL			33-37
RDW	16.9	H		%			11.5-14.5
Platelet	437			1000/ $\mu$ L			145-409
<b>RBC Morphology</b>							
Anisocytosis	1+						
Hypochromia	1+						
Microcytosis	2++						
Polychromasia	1+						
Elliptocytosis	1+						
Ovalocytosis	1+						
Acanthocytosis	1+						
<b>Leukocyte Differential Count</b>							
Neutrophil#	5.67			$\times 1000/\mu$ L			2-7
Lymphocyte#	1.64			$\times 1000/\mu$ L			0.8-4
Monocyte#	0.69			$\times 1000/\mu$ L			0.12-1.2
Eosinophil#	0.63	H		$\times 1000/\mu$ L			0.02-0.5
Basophil#	0.12	H		$\times 1000/\mu$ L			0.0-0.1
Neutrophil%	66			%			50-70
Lymphocyte%	12	L		%			20-40
Monocyte%	8			%			1-12
Band Cell%	3			%			0-6%
Eosinophil%	9	H		%			0.5-5
Basophil%	2	H		%			0-1



شماره پذیرش :

مراجعه: خانم

سن : ۸۴ سال  
اشتراک :

پزشک معالج :  
تاریخ پذیرش :

صفحه: ۱ از ۱ سابقه : ۱۰

## Biochemistry

	<u>Result</u>		<u>Unit</u>	<u>Method</u>	<u>Reference Interval</u>
Hours After Meal	11:30		Hours		
Iron	<15	L	µg/dL	Ferrozine	F:23-165
<b>Unsaturated Iron Binding Capacity(UIBC)</b>					
UIBC	425	H	µg/dl	Ferrozine	112-346
Saturation of Transferrin	3.4	L	%		20-50%
TIBC	440		µg/dl	Imm.Turbid	250-450

نمونه ۹۹۲۲۲۱



شماره پذیرش :

مراجعه: خانم

سن : ۸۴ سال

اشتراک :

پزشک معالج :

تاریخ پذیرش :

صفحه: ۱ از ۱ سابقه : ۱۰

## Hormone

	<u>Result</u>		<u>Unit</u>	<u>Method</u>	<u>Reference Interval</u>
Ferritin	12.16	L	ng/mL	CLIA	13-150 ID/IDA:<20 Usually excluded ID/IDA:>100 ID in Haemodialysis CKD <200 ID in non haemolysis CKD <100  ID: Iron Deficiency IDA: Iron Deficiency Anemia

### Ferritin

